Previous issues
-
Previous issues
Volume 29(4) Oct 2023
Print ISSN: 2287-2728
Online ISSN: 2287-285X
- Special Reviews Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
- Gi-Ae Kim, Joon Ho Moon, Won Kim
- Clin Mol Hepatol. 2023;29(4):831-843.
- Waiting for the changes after the adoption of steatotic liver disease
- Eileen L. Yoon, Dae Won Jun
- Clin Mol Hepatol. 2023;29(4):844-850.
- Reviews Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy
- Takako Inoue, Takehisa Watanabe, Yasuhito Tanaka
- Clin Mol Hepatol. 2023;29(4):851-868.
- Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm
- Yao-Chun Hsu, Cheng-Hao Tseng, Jia-Horng Kao
- Clin Mol Hepatol. 2023;29(4):869-890.
- Hepatorenal syndrome: Current concepts and future perspectives
- Chan-Young Jung, Jai Won Chang
- Clin Mol Hepatol. 2023;29(4):891-908.
- The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
- Landon L. Chan, Stephen L. Chan
- Clin Mol Hepatol. 2023;29(4):909-923.
- Evidence-based hyponatremia management in liver disease
- Ji Young Ryu, Seon Ha Baek, Sejoong Kim
- Clin Mol Hepatol. 2023;29(4):924-944.
- Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma
- Hwa Kyung Byun, Changhwan Kim, Jinsil Seong
- Clin Mol Hepatol. 2023;29(4):945-957.
- Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma
- Sung Uk Lee, Tae Hyun Kim
- Clin Mol Hepatol. 2023;29(4):958-968.
- Editorials From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
- Ming-Lun Yeh, Ming-Lung Yu
- Clin Mol Hepatol. 2023;29(4):969-972.
- Adding to the confusion in more than just the name
- Jacob George
- Clin Mol Hepatol. 2023;29(4):973-976.
- Novel paradigm in the treatment of hepatocellular carcinoma: Anticipating breakthroughs with particle therapy
- Sang Min Yoon
- Clin Mol Hepatol. 2023;29(4):977-979.
- Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean?
- Eugene Han, Yong-ho Lee
- Clin Mol Hepatol. 2023;29(4):980-983.
- Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma?
- Hyo-Cheol Kim
- Clin Mol Hepatol. 2023;29(4):984-986.
- Original Articles Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity
- Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe
- Clin Mol Hepatol. 2023;29(4):987-1001.
- Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study
- Vy H. Nguyen, Isaac Le, Audrey Ha, Richard Hieu Le, Nicholas Ajit Rouillard, Ashley Fong, Surya Gudapati, Jung Eun Park, Mayumi Maeda, Scott Barnett, Ramsey Cheung, Mindie H. Nguyen
- Clin Mol Hepatol. 2023;29(4):1002-1012.
- Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis
- Ha Il Kim, Jihyun An, Seungbong Han, Ju Hyun Shim
- Clin Mol Hepatol. 2023;29(4):1013-1028.
- Prognostic role of computed tomography analysis using deep learning algorithm in patients with chronic hepatitis B viral infection
- Jeongin Yoo, Heejin Cho, Dong Ho Lee, Eun Ju Cho, Ijin Joo, Sun Kyung Jeon
- Clin Mol Hepatol. 2023;29(4):1029-1042.
- Letters to the Editor Letter regarding “Evidence-based hyponatremia management in liver disease”
- Daphne J. Theodorou, Stavroula J. Theodorou, Ioannis V. Mitselos
- Clin Mol Hepatol. 2023;29(4):1043-1045.
- Letter regarding “Risk factors in nonalcoholic fatty liver disease”
- Abhijit Pratap, Umesh More, Pradnya Phalak, Anita Deshmukh
- Clin Mol Hepatol. 2023;29(4):1046-1047.
- Correspondences Correspondence on Letter regarding “Evidence-based hyponatremia management in liver disease”
- Ji Young Ryu, Seon Ha Baek, Sejoong Kim
- Clin Mol Hepatol. 2023;29(4):1048-1049.
- Correspondence on Letter regarding “Risk factors in nonalcoholic fatty liver disease”
- Eileen L. Yoon, Dae Won Jun
- Clin Mol Hepatol. 2023;29(4):1050-1051.
- Snapshot The role of the hepatic autonomic nervous system
- Qiankun Luo, Pan Liu, Yifei Dong, Tao Qin
- Clin Mol Hepatol. 2023;29(4):1052-1055.